Ironwood Pharmaceuticals Return on Tangible Equity 2010-2025 | IRWD

Current and historical return on tangible equity values for Ironwood Pharmaceuticals (IRWD) over the last 10 years. Return on tangible equity can be defined as the amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity.
Ironwood Pharmaceuticals Return On Tangible Equity Historical Data
Date TTM Net Income Tangible Equity Return on Tangible Equity
2025-03-31 $-0.03B $-0.34B 10.00%
2024-12-31 $0.00B $-0.30B -0.31%
2024-09-30 $0.00B $-0.31B 0.60%
2024-06-30 $0.01B $-0.33B -2.69%
2024-03-31 $-1.05B $-0.33B 308.28%
2023-12-31 $-1.00B $-0.35B 1237.04%
2023-09-30 $-0.95B $-0.33B -561.65%
2023-06-30 $-0.92B $-0.35B -229.39%
2023-03-31 $0.18B $0.71B 29.32%
2022-12-31 $0.18B $0.65B 30.51%
2022-09-30 $0.17B $0.59B 29.72%
2022-06-30 $0.17B $0.53B 30.93%
2022-03-31 $0.53B $0.52B 95.13%
2021-12-31 $0.53B $0.61B 116.81%
2021-09-30 $0.53B $0.58B 167.59%
2021-06-30 $0.51B $0.51B 294.07%
2021-03-31 $0.14B $0.11B 400.00%
2020-12-31 $0.11B $0.06B -1050.00%
2020-09-30 $0.07B $0.01B -146.94%
2020-06-30 $0.06B $-0.04B -66.29%
2020-03-31 $0.05B $-0.07B -34.14%
2019-12-31 $0.02B $-0.09B -11.91%
2019-09-30 $0.00B $-0.15B 1.98%
2019-06-30 $-0.20B $-0.22B 93.32%
2019-03-31 $-0.26B $-0.24B 125.15%
2018-12-31 $-0.28B $-0.20B 146.35%
2018-09-30 $-0.25B $-0.20B 140.72%
2018-06-30 $-0.11B $-0.20B 63.46%
2018-03-31 $-0.11B $-0.18B 63.98%
2017-12-31 $-0.12B $-0.15B 74.17%
2017-09-30 $-0.14B $-0.18B 98.62%
2017-06-30 $-0.14B $-0.16B 110.34%
2017-03-31 $-0.12B $-0.14B 104.72%
2016-12-31 $-0.08B $-0.10B 137.82%
2016-09-30 $-0.08B $-0.12B 762.79%
2016-06-30 $-0.10B $-0.11B -212.15%
2016-03-31 $-0.12B $0.09B -114.55%
2015-12-31 $-0.14B $0.10B -140.94%
2015-09-30 $-0.17B $0.10B -167.25%
2015-06-30 $-0.16B $0.14B -159.01%
2015-03-31 $-0.17B $0.07B -170.02%
2014-12-31 $-0.19B $0.09B -143.94%
2014-09-30 $-0.20B $0.11B -171.07%
2014-06-30 $-0.22B $0.14B -197.79%
2014-03-31 $-0.23B $0.19B -203.56%
2013-12-31 $-0.27B $0.04B -341.25%
2013-09-30 $-0.27B $0.08B -248.83%
2013-06-30 $-0.16B $0.14B -118.32%
2013-03-31 $-0.13B $0.06B -101.95%
2012-12-31 $-0.07B $0.14B -47.17%
2012-09-30 $-0.04B $0.18B -24.62%
2012-06-30 $-0.11B $0.13B -81.40%
2012-03-31 $-0.08B $0.16B -64.22%
2011-12-31 $-0.07B $0.11B -52.21%
2011-09-30 $-0.07B $0.11B -51.09%
2011-06-30 $-0.06B $0.13B -37.81%
2011-03-31 $-0.06B $0.15B -34.00%
2010-12-31 $-0.05B $0.16B -30.68%
2010-09-30 $-0.07B $0.17B -111.59%
2010-06-30 $-0.07B $0.17B 128.91%
2010-03-31 $-0.07B $0.19B 71.69%
2009-12-31 $-0.07B $-0.30B 49.48%
Sector Industry Market Cap Revenue
Medical MED-DRUGS $0.114B $0.351B
Ironwood Pharmaceuticals, Inc. focuses on the development and commercialization of treatments primarily addressing gastrointestinal diseases. Linzess was launched in collaboration with Allergan for patients suffering from irritable bowel syndrome (IBS-C; 290 mcg) with constipation or chronic idiopathic constipation. Ironwood and AbbVie co-develop & co-commercialize Linzess in all other territories world wide. Linzess is marketed by Allergan for IBS-C in Europe and Canada under the brand name Constella. The company receives royalties on sales of Constella in Europe and Canada from AbbVie. In Japan, it has partnered with Astellas Pharma for the development and commercialization of Linzess and with AstraZeneca in China, Hong Kong & Macau. Linzess received approval for IBS-C indication in Japan for chronic constipation and in China for IBS-C. The company completed the spin-off of its soluble guanylate cyclase segment into a separate, publicly traded company, Cyclerion Therapeutics.
Stock Name Country Market Cap PE Ratio
Chugai Pharmaceutical (CHGCY) JP $80.630B 30.25
Zoetis (ZTS) US $69.973B 26.11
Takeda Pharmaceutical (TAK) JP $46.997B 9.35
Daiichi Sankyo, - (DSNKY) JP $42.922B 22.00
BeOne Medicines - (ONC) KY $27.080B 0.00
Sandoz Group AG (SDZNY) CH $23.434B 0.00
Merck (MKKGY) DE $16.421B 12.03
Summit Therapeutics (SMMT) US $15.269B 0.00
Shionogi (SGIOY) JP $14.428B 0.00
United Therapeutics (UTHR) US $13.115B 11.60
Neurocrine Biosciences (NBIX) US $12.524B 42.90
Orion OYJ (ORINY) FI $10.594B 28.65
IPSEN (IPSEY) FR $9.831B 0.00
Corcept Therapeutics (CORT) US $7.569B 61.53
Stevanato Group S.p.A (STVN) IT $7.053B 43.13
Madrigal Pharmaceuticals (MDGL) US $6.344B 0.00
Hikma Pharmaceuticals Plc (HKMPF) GB $6.153B 0.00
Grifols, S.A (GRFS) ES $6.030B 0.00
Ionis Pharmaceuticals (IONS) US $5.954B 0.00
Ono Pharmaceutical (OPHLF) JP $5.031B 15.30
Soleno Therapeutics (SLNO) US $4.031B 0.00
Hypermarcas (HYPMY) BR $3.075B 20.23
Crinetics Pharmaceuticals (CRNX) US $2.824B 0.00
Catalyst Pharmaceuticals (CPRX) US $2.742B 9.61
AMNEAL PHARMACEUTICALS, INC (AMRX) US $2.451B 13.25
BioCryst Pharmaceuticals (BCRX) US $2.113B 0.00
NewAmsterdam Pharma (NAMS) NL $2.016B 0.00
Indivior (INDV) US $1.932B 8.19
Centessa Pharmaceuticals (CNTA) GB $1.660B 0.00
Endo (NDOI) US $1.595B 0.00
ARS Pharmaceuticals (SPRY) US $1.552B 0.00
Evotec AG (EVO) DE $1.335B 0.00
Ocular Therapeutix (OCUL) US $1.295B 0.00
Guardian Pharmacy Services (GRDN) US $1.272B 0.00
Dyne Therapeutics (DYN) US $1.173B 0.00
Harrow (HROW) US $1.125B 0.00
Aurinia Pharmaceuticals Inc (AUPH) CA $1.050B 21.00
Enliven Therapeutics (ELVN) US $1.045B 0.00
Verve Therapeutics (VERV) US $0.986B 0.00
Akebia Therapeutics (AKBA) US $0.967B 0.00
Collegium Pharmaceutical (COLL) US $0.958B 5.17
Avadel Pharmaceuticals (AVDL) IE $0.888B 0.00
Ardelyx (ARDX) US $0.852B 0.00
Elite Pharmaceuticals (ELTP) US $0.793B 0.00
Cronos Group (CRON) CA $0.717B 0.00
Xeris Biopharma Holdings (XERS) US $0.705B 0.00
Xencor (XNCR) US $0.608B 0.00
KalVista Pharmaceuticals (KALV) US $0.604B 0.00
Altimmune (ALT) US $0.570B 0.00
USANA Health Sciences (USNA) US $0.569B 12.37
Relay Therapeutics (RLAY) US $0.547B 0.00
Regulus Therapeutics (RGLS) US $0.546B 0.00
Bioventus (BVS) US $0.538B 13.65
Theravance Biopharma (TBPH) US $0.532B 0.00
AleAnna (ANNA) US $0.504B 0.00
Zevra Therapeutics (ZVRA) US $0.494B 0.00
Amylyx Pharmaceuticals (AMLX) US $0.450B 0.00
Oruka Therapeutics (ORKA) US $0.437B 0.00
Siga Technologies (SIGA) US $0.437B 9.13
Tourmaline Bio (TRML) US $0.427B 0.00
Organogenesis (ORGO) US $0.410B 0.00
Liminatus Pharma (LIMN) US $0.375B 0.00
Savara (SVRA) US $0.356B 0.00
Rigel Pharmaceuticals (RIGL) US $0.338B 9.14
Aquestive Therapeutics (AQST) US $0.323B 0.00
Heron Therapeutics (HRTX) US $0.305B 0.00
Nature's Sunshine Products (NATR) US $0.271B 24.86
Tonix Pharmaceuticals Holding (TNXP) US $0.238B 0.00
Esperion Therapeutics (ESPR) US $0.212B 0.00
Nanobiotix S.A (NBTX) FR $0.211B 0.00
MediWound (MDWD) IL $0.206B 0.00
OmniAb (OABI) US $0.194B 0.00
ProKidney (PROK) US $0.193B 0.00
4D Molecular Therapeutics (FDMT) US $0.191B 0.00
Profound Medical (PROF) CA $0.191B 0.00
Aldeyra Therapeutics (ALDX) US $0.183B 0.00
Larimar Therapeutics (LRMR) US $0.166B 0.00
Aclaris Therapeutics (ACRS) United States $0.157B 0.00
Galectin Therapeutics (GALT) US $0.153B 0.00
Journey Medical (DERM) US $0.152B 0.00
Innate Pharma SA (IPHYF) FR $0.145B 0.00
Avita Medical (RCEL) US $0.137B 0.00
VAXART, INC (VXRT) US $0.132B 0.00
Lexeo Therapeutics (LXEO) US $0.130B 0.00
Lyell Immunopharma (LYEL) US $0.129B 0.00
Inhibikase Therapeutics (IKT) US $0.123B 0.00
Protara Therapeutics (TARA) US $0.118B 0.00
Achieve Life Sciences (ACHV) Canada $0.116B 0.00
Korro Bio (KRRO) US $0.116B 0.00
Champions Oncology (CSBR) US $0.115B 18.84
Nektar Therapeutics (NKTR) US $0.106B 0.00
Fractyl Health (GUTS) US $0.105B 0.00
Cardiol Therapeutics (CRDL) CA $0.102B 0.00
Corbus Pharmaceuticals Holdings (CRBP) US $0.101B 0.00
Cassava Sciences (SAVA) US $0.096B 0.00
Wellgistics Health (WGRX) US $0.087B 0.00
Nutriband (NTRB) US $0.087B 0.00
Surrozen (SRZN) US $0.086B 0.00
Dominari Holdings (DOMH) US $0.083B 0.00
Arch Biopartners (ACHFF) Canada $0.083B 0.00
Unicycive Therapeutics (UNCY) US $0.080B 0.00
ESSA Pharma (EPIX) CA $0.077B 0.00
Vivani Medical (VANI) US $0.075B 0.00
Pyxis Oncology (PYXS) US $0.072B 0.00
Inotiv (NOTV) US $0.070B 0.00
Cumberland Pharmaceuticals (CPIX) US $0.065B 48.33
Assertio Holdings (ASRT) US $0.060B 0.00
Allergy Therapeutics (AGYTF) GB $0.059B 0.00
PMV Pharmaceuticals (PMVP) US $0.057B 0.00
NRx Pharmaceuticals (NRXP) US $0.056B 0.00
Rafael Holdings (RFL) US $0.055B 0.00
Metagenomi (MGX) US $0.054B 0.00
Verrica Pharmaceuticals (VRCA) US $0.054B 0.00
Gain Therapeutics (GANX) US $0.053B 0.00
Telomir Pharmaceuticals (TELO) US $0.052B 0.00
Context Therapeutics (CNTX) US $0.051B 0.00
Avalo Therapeutics (AVTX) US $0.050B 0.00
Century Therapeutics (IPSC) US $0.050B 0.00
Klotho Neurosciences (KLTO) US $0.050B 0.00
Prelude Therapeutics (PRLD) US $0.049B 0.00
Mural Oncology (MURA) IE $0.042B 0.00
Iterum Therapeutics (ITRM) IE $0.040B 0.00
ElectroCore (ECOR) US $0.038B 0.00
Karyopharm Therapeutics (KPTI) US $0.038B 0.00
Acrivon Therapeutics (ACRV) United States $0.037B 0.00
Jupiter Neurosciences (JUNS) US $0.037B 0.00
PolyPid (PYPD) IL $0.033B 0.00
Reviva Pharmaceuticals Holdings (RVPH) US $0.033B 0.00
China SXT Pharmaceuticals (SXTC) CN $0.029B 0.00
SCYNEXIS (SCYX) US $0.029B 0.00
Enlivex Therapeutics (ENLV) IL $0.026B 0.00
Tempest Therapeutics (TPST) US $0.025B 0.00
FibroGen (FGEN) US $0.023B 0.00
Relmada Therapeutics (RLMD) US $0.023B 0.00
DURECT (DRRX) US $0.021B 0.00
Natural Alternatives (NAII) US $0.020B 0.00
BioVie (BIVI) US $0.019B 0.00
Mannatech (MTEX) US $0.019B 0.00
Carisma Therapeutics (CARM) US $0.018B 0.00
BioLineRx (BLRX) IL $0.018B 0.00
Ernexa Therapeutics (ERNA) US $0.018B 0.00
Lipocine (LPCN) US $0.018B 0.00
Vivos Therapeutics (VVOS) US $0.016B 0.00
MARKER THERAPEUTICS, INC (MRKR) US $0.016B 0.00
CASI Pharmaceuticals (CASI) CN $0.016B 0.00
ProPhase Labs (PRPH) US $0.014B 0.00
Lyra Therapeutics (LYRA) US $0.014B 0.00
VYNE Therapeutics (VYNE) US $0.014B 0.00
TherapeuticsMD (TXMD) US $0.013B 0.00
Cosmos Health (COSM) US $0.012B 0.00
Minerva Neurosciences (NERV) US $0.012B 2.16
Scienture Holdings (SCNX) US $0.012B 0.00
Citius Pharmaceuticals (CTXR) US $0.011B 0.00
Phio Pharmaceuticals (PHIO) US $0.011B 0.00
Mangoceuticals (MGRX) US $0.011B 0.00
Ainos (AIMD) US $0.010B 0.00
Kiora Pharmaceuticals (KPRX) US $0.010B 0.00
GlycoMimetics (CBIO) US $0.010B 0.00
Talphera (TLPH) US $0.009B 0.00
Traws Pharma (TRAW) US $0.009B 0.00
Addex Therapeutics (ADXN) Switzerland $0.009B 0.00
NLS Pharmaceutics (NLSP) CH $0.009B 0.00
Biomerica (BMRA) US $0.008B 0.00
Nuvilex (PMCB) US $0.007B 0.00
Alaunos Therapeutics (TCRT) US $0.007B 0.00
SHINECO (SISI) CN $0.007B 0.00
Incannex Healthcare (IXHL) AU $0.006B 0.00
TransCode Therapeutics (RNAZ) US $0.006B 0.00
Aptorum Group (APM) GB $0.005B 0.00
XTL Biopharmaceuticals (XTLB) IL $0.005B 0.00
Quoin Pharmaceuticals (QNRX) US $0.005B 0.00
Sonoma Pharmaceuticals (SNOA) US $0.005B 0.00
Redhill Biopharma (RDHL) IL $0.004B 0.00
Indaptus Therapeutics (INDP) US $0.004B 0.00
Xenetic Biosciences (XBIO) US $0.004B 0.00
CERo Therapeutics Holdings (CERO) US $0.004B 0.00
Heatwurx (PCSA) US $0.004B 0.00
Clearmind Medicine (CMND) CA $0.004B 0.00
SciSparc (SPRC) IL $0.003B 0.00
XORTX Therapeutics (XRTX) CA $0.003B 0.00
Plus Therapeutics (PSTV) US $0.003B 0.00
PainReform (PRFX) IL $0.003B 0.00
Galmed Pharmaceuticals (GLMD) IL $0.003B 0.00
60 Degrees Pharmaceuticals (SXTP) US $0.003B 0.00
InMed Pharmaceuticals (INM) CA $0.003B 0.00
Jaguar Animal Health (JAGX) US $0.003B 0.00
Aditxt (ADTX) United States $0.003B 0.00
Qualigen Therapeutics (QLGN) US $0.003B 0.00
Salarius Pharmaceuticals (SLRX) US $0.002B 0.00
TNF Pharmaceuticals (TNFA) US $0.002B 0.00
Conduit Pharmaceuticals (CDT) US $0.002B 0.00
Shuttle Pharmaceuticals Holdings (SHPH) US $0.002B 0.00
Universe Pharmaceuticals INC (UPC) CN $0.000B 0.00
4D Pharma (LBPS) GB $0.000B 0.00
MEI Pharma (MEIP) US $0.000B 0.00
Patheon (PTHN) NL $0.000B 0.00
RVL Pharmaceuticals (RVLP) US $0.000B 0.00
Silence Therapeutics (SLN) GB $0.000B 0.00